DNA RNA and Cells

10 Oct 2016 Oxford BioMedica Announces Publication of Pioneering RetinoStatĀ® (OXB-201) Phase I Study Data in the Journal, Human Gene Therapy
09 Oct 2016 Kite Pharma Presents 12-Month Follow-Up Data from ZUMA-1 Phase 1 at the European Society for Medical Oncology (ESMO) Annual Congress
09 Oct 2016 AveXis Reports Interim Data from Ongoing Phase 1 Clinical Trial of AVXS-101 in Spinal Muscular Atrophy Type 1 as Presented at the International Annual Congress of the World Muscle Society
09 Oct 2016 New Data Presented at World Muscle Society Congress Support Potential Benefit of Investigational Treatment Nusinersen in Spinal Muscular Atrophy
09 Oct 2016 Adaptimmune Provides Update on Study of NY-ESO SPEARĀ® T-cell Therapy in Synovial Sarcoma at the European Society for Medical Oncology (ESMO) 2016 Congress
07 Oct 2016 Abeona Therapeutics Announces Publication of Preclinical Data Supporting Clinical Translation of Juvenile Batten Disease Gene Therapy
06 Oct 2016 Kite Pharma Initiates Phase 1b/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL)
06 Oct 2016 Alnylam Pharmaceuticals Discontinues Revusiran Development
06 Oct 2016 AUM LifeTech Develops A New Approach To Combat HIV By Using FANA RNA Silencing Technology To Inhibit HIV Replication
05 Oct 2016 Capricor Therapeutics Completes Enrollment in Phase II ALLSTAR Clinical Trial
05 Oct 2016 CIK Treatment Extends Progression-free Survival of Glioblastoma Patients by 1.5 Times
05 Oct 2016 Transgene Presents Data on Improved Cytotoxic Activity of Oncolytic Viruses Expressing Intrabodies in Resistant Tumor Cell Lines
05 Oct 2016 Bone Therapeutics Reports Positive Efficacy Data for the ALLOBĀ® Phase IIA Spinal Fusion Trial
29 Sep 2016 Alnylam Presents Clinical and Non-Clinical Data Demonstrating Continued RNAi Platform Optimization and Leadership in the Development of RNA-Based Therapeutics at 12th Annual Meeting of the Oligonucleotide Therapeutics Society
29 Sep 2016 Sarepta Therapeutics Announces First Patient Dosed in Phase III Clinical Trial of SRP-4045 and SRP-4053 for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping
27 Sep 2016 Kite Pharma Announces Positive Topline KTE-C19 Data from ZUMA-1 Pivotal Trial in Patients with Aggressive Non-Hodgkin Lymphoma (NHL)
27 Sep 2016 MiNA Therapeutics Announces Presentation of Pre-Clinical Data Supporting On-Target Mechanism of Action of Clinical Candidate MTL-CEBPA
26 Sep 2016 Idera Pharmaceuticals Reports Promising Data from Ongoing Phase 1 Dose Escalation in Clinical Trial of Intra-tumoral IMO-2125 in Combination with Ipilimumab in Patients with PD-1 Refractory Metastatic Melanoma
26 Sep 2016 Abeona Therapeutics Enrolls First Patient in Phase 2 for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
26 Sep 2016 Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy
25 Sep 2016 Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1
22 Sep 2016 First Patient Enrolled in Toca 6, Tocagen's Trial for Metastatic Cancers Evaluating Intravenously Delivered Toca 511 Virus
22 Sep 2016 Mirna Therapeutics Halts Phase 1 Clinical Study of MRX34
22 Sep 2016 Akcea Announces Publication in The Lancet of Clinical Results with Lp(a)-Lowering Drugs Designed to Treat Cardiovascular Disease
20 Sep 2016 AmpliPhi Biosciences Provides Update on Phase 1 Trial in Chronic Rhinosinusitis Patients

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top